Affiliations: J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Correspondence:
[*]
Correspondence to: Andreas Charidimou, MD, PhD, Harvard Medical School, Kistler Stroke Research Center, Massachusetts General Hospital, 175 Cambridge St, Suite 300, Boston, MA 02114, USA. Tel.: +1 617 643 3941; Fax: +1 617 643 3939; E-mail: andreas.charidimou.09@ucl.ac.uk.
Abstract: Cerebral amyloid angiopathy– related inflammation (CAA-ri) is an aggressive disease subtype of CAA with characteristic clinical and radiological findings. CAA-ri is an important diagnosis to reach in clinical practice, as patients typically respond to prompt immunosuppressive treatment. A definitive diagnosis of CAA-ri still requires a brain biopsy, and hence developing non-invasive diagnostic criteria and biomarkers for this syndrome are key priorities in the field. CAA-ri has gained additional interest for its notable similarities to amyloid-related imaging abnormalities, a complication of immunotherapy treatments in Alzheimer’s disease patients. In this commentary, the current state of biomarkers research for CAA-ri and recently suggested diagnostic criteria are put into context.
